Showing 6161-6170 of 7113 results for "".
- Alma Lasers Hosts Special Programs at the 34th ASLMS Conference in Phoenixhttps://practicaldermatology.com/news/20140403-alma_lasers_hosts_special_programs_at_the_34th_aslms_conference_in_phoenix/2459279/The ASLMS, provider of laser, light-based, radio frequency and ultrasound technologies, invites guests to hear from leading experts. Michael Gold, of Gold Skin Care in Nashville, Tennessee, will moderate the night's discussion. Others include: Macrene Alexiades-Armenakas, MD, director a
- Lithera to Present at the 13th Annual Needham Healthcare Conferencehttps://practicaldermatology.com/news/20140402-lithera_to_present_at_the_13th_annual_needham_healthcare_conference/2459280/Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that George Mahaffey, President and Chief Executive Officer, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April
- Cosmetic Treatments Jump 25 Percent in 2013: ASDS Surveyhttps://practicaldermatology.com/news/20140401-cosmetic_treatments_jump_25_percent_in_2013_asds_survey/2459283/The number of cosmetic procedures performed by members of the American Society for Dermatologic Surgery jumped to nearly 6.5 million in 2013 – an increase of 25 percent over the previous year, the ASDS Survey on Dermatologic Procedures shows.
- International Society of Hair Restoration Surgery Achieves ACCME Accreditation With Commendation for Educational Activitieshttps://practicaldermatology.com/news/20140401-international_society_of_hair_restoration_surgery__achieves_accme_accreditation_with_commendation_for_educational_activities/2459284/The International Society of Hair Restoration Surgery (ISHRS) – the largest international medical association of hair restoration surgeons – announced today that the Accreditation Council for Continuing Medical Education (ACCME) awarded the ISHRS Accreditation with Commendation for six years as a pr
- Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexeshttps://practicaldermatology.com/news/20140401-revance_therapeutics_added_to_russell_2000r_and_3000r_indexes/2459286/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following the reconstitution of Russell Investment Group's family of U.S. indexes after market close on March 31, 2014.
- Image Skincare Releases Vectorize Technology™https://practicaldermatology.com/news/20140401-image_skincare_releases_vectorize_technology/2459287/Vectorize Technology has revolutionized ingredient delivery by enabling up to 100 treatments in a single application. Marc Ronert, M.D., Ph.D., President and Medical Director of Image Skincare said, "Vectorize Technology™ is a game-changer. It will revolutionize the way the world thinks a
- Frost & Sullivan Commends Sensus for the Development of SRT-100™ and SRT-100 Vision™, its Low-energy Radiation Therapy Systems for Treating Skin Cancerhttps://practicaldermatology.com/news/20140331-frost__sullivan_commends_sensus_for_the_development_of_srt-100_and_srt-100_vision_its_low-energy_radiation_therapy_systems_for_treating_skin_cancer/2459289/Based on its recent analysis of the non-melanoma skin cancer therapy market, Frost & Sullivan recognizes Sensus Healthcare LLC with the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. Sensus uses a technique known as superficial radiation therapy (SRT) in its two lo
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- Phase 3 Results for Novartis' Secukinumab Reportedhttps://practicaldermatology.com/news/20140322-phase_3_results_for_novartis_secukinumab_reported/2459300/Results from the Phase III FEATURE and JUNCTURE studies show Novartis' secukinumab (AIN457), a selective interleukin-17A (IL-17A) inhibitor, met both co-primary endpoints at Week 12 based on Psoriasis Area and Severity Index (PASI) 75 and Investigator's Global Assessment modified 2011 (IGA mod 2011)
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas